Nestlé divests its peanut allergy treatment business
Nestlé has divested Palforzia, its peanut allergy treatment business, to Stallergenes Greer, a biopharmaceutical company that specialises in the diagnosis and treatment of allergies. The transaction was closed upon signing.
Last year, Nestlé announced it would conduct a strategic review of Palforzia. It will now receive milestone payments and ongoing royalties from Stallergenes Greer.
Greg Behar, CEO of Nestlé Health Science, said Nestlé is confident that Stallergenes Greer will take Palforzia forward, allowing Nestlé Health Science to focus on its strengths and growth drivers.
There will be a customary transition period to ensure business continuity and give patients uninterrupted access to the treatment.
Leadership change at CCEP Australia next year
Miles Karemacher has been appointed as Managing Director of Coca-Cola Europacific Partners...
ACCC alleges anti-competitive conduct by Australian egg producer
The ACCC has initiated civil action over its allegations that Australian egg producers have...
Wine mentoring program underway in NZ
The program matches mentors with mentees who are looking to take the next step with their careers...
